Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Supports Capped EPO Payments For ESRD, But Only After Further Study

This article was originally published in The Pink Sheet Daily

Executive Summary

House Ways and Means Committee Chairman Thomas recommends steps to reduce EPO usage in dialysis facilities during a Dec. 6 hearing.

You may also be interested in...



Rep. Thomas Teams Up With Insmed To Promote Follow-on Biologics

Former Rep. Bill Thomas continues his crusade for follow-ons and against Amgen in his new role as consultant to Richmond, Va.-based Insmed, which has big plans for follow-on biologics.

Rep. Thomas Teams Up With Insmed To Promote Follow-on Biologics

Former Rep. Bill Thomas continues his crusade for follow-ons and against Amgen in his new role as consultant to Richmond, Va.-based Insmed, which has big plans for follow-on biologics.

Epoetin Alfa Increases Cardiovascular Risks When Targeting High Hemoglobin Levels, J&J Study Finds

Patients with chronic kidney disease, when treated with a more aggressive dose of Procrit, had a higher risk but no incremental improvement in quality of life.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS063637

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel